LYEL Lyell Immunopharma, Inc. Insider Trading

Major VC investor ARCH Venture Partners IX bought 488,090 shares of LYEL at $25.61 (+52.0% stake increase to 1.43M shares) amid $-38.8M net loss.

ARCH Venture Partners IX, a 10% owner, purchased 488,090 shares at $25.61, expanding its position by 52.0% from 938,438 to 1.43M shares. This substantial commitment of capital ($12.5M) occurs while Lyell reports severe financial stress: latest quarterly revenue of $15,000.00, a $-38.8M net loss, and annual revenue contraction of -53.1%. The company remains deeply unprofitable. The stock currently trades at $25.50 (within 33.9% of its 52-week high of $38.60), suggesting the purchase was not made at a deeply distressed valuation. This concentrated investment increase by a major shareholder warrants scrutiny into what specific clinical, strategic, or operational developments ARCH perceives that justify a 52% increase in exposure to a cash-burning early-stage biotech at current market prices.

ARCH Venture Fund XIII acquired 488,090 shares of LYEL at $25.61 for $12.5M, raising stake to 1.43M shares amid unprofitable fundamentals.

ARCH Venture Fund XIII, a 10% shareholder, purchased 488,090 shares at $25.61 on 2026-03-06, increasing its stake by 52.0% from 938,438 to 1.43M shares. The transaction occurred at a price 33.9% below the 52-week high of $38.60 but 228% above the 52-week low of $7.80, near recent momentum (+12.3% over 30 days, -12.9% over 90 days). The acquisition is notable given the company's deteriorating fundamentals: LYEL generated only $15.0K in latest-quarter revenue (annualized run-rate concerns), posted a net loss of $-38.8M, and experienced -53.1% annual revenue decline with sustained unprofitability. A venture capital anchor doubling down on a cash-burn biotech asset during a revenue collapse warrants scrutiny of the company's clinical/financing runway and the strategic rationale underlying this substantial $12.5M incremental commitment.

Director Brawley Otis W purchases 35.6K shares of LYEL at $0.56 (initial holding)

BRAWLEY OTIS W, a director, acquired 35,640 shares at $0.56 per share on 2025-03-31, establishing an initial position in Lyell Immunopharma. The purchase occurred at a price well below the current $10.15 and substantially below the 52-week high of $60.20, though the stock is -83.1% from its 52-week peak and -23.3% over the past 30 days. The company is operationally challenged, with quarterly revenue of $34,000.00 against a net loss of $-44,583,000.00, and annual revenue declined -53.1% year-over-year; the company remains unprofitable on a full-year basis. An insider's initial entry into a distressed biotech warrants close examination of both timing context and any concurrent capital or strategic developments, given the magnitude of operational losses relative to revenue.

Director Sumant buys 200.0K shares of LYEL at $0.58 on 2025-03-21; stock now $10.50, cluster buy with 3 other insiders in 14 days

Ramachandra Sumant (Director) purchased 200,000 shares at $0.58 on 2025-03-21, establishing his initial position in Lyell Immunopharma. This transaction is part of a cluster pattern: 3 other insiders also bought within the past 14 days, indicating coordinated insider accumulation during a period of significant stock pressure—the stock has declined 82.6% from its 52-week high and is down 25.1% over the past 30 days. The company reported revenue of $34.0K in its latest quarter with a net loss of $44.6M and annual revenue growth of -53.1%, reflecting deep operational challenges. The confluence of insider cluster buying amid severe valuation collapse and deteriorating fundamentals merits attention to whether insiders view current prices as exploitable—or whether the poor financial trajectory portends further downside.

Director Klausner buys 158,000 LYEL shares at $0.60; stock now $9.67, -83.9% from 52-week high; cluster pattern with 2 other insiders in 14 days.

Richard Klausner, a director, purchased 158,000 shares at $0.60 on 2025-03-14, increasing his holdings by 23.1% to 843,365 shares. This purchase occurs amid significant price deterioration: the stock has fallen -20.8% over the past 30 days and -83.9% from its 52-week high of $60.20. A cluster pattern is present, with 2 other insiders also buying within the past 14 days. The company's fundamentals remain deeply challenged—quarterly revenue was $34,000.00 while net income was $-44,583,000.00, and annual revenue contracted -53.1% year-over-year. The combination of substantial insider accumulation during a steep drawdown, alongside coordinated purchasing by other board members, warrants examination of whether this reflects conviction in near-term recovery or represents a response to other factors.

LYEL CEO Lynn bought 175.0K shares at $0.61 amid cluster buy; stock down -83.9% from 52-week high at $60.20.

Seely Lynn, President and CEO, purchased 175,000 shares at $0.61 on 2025-03-14, increasing holdings by 32.6% to 712,500 shares. This transaction occurs within a broader cluster pattern: 2 other insiders also bought within the past 14 days. Notably, the company is unprofitable, with net income of $-44,583,000.00 in its most recent full fiscal year and quarterly revenue of only $34,000.00, alongside an annual revenue decline of -53.1%. The stock trades at $9.67, down -83.9% from its 52-week high of $60.20 and down -20.8% over the past 30 days. This purchase by the CEO, combined with concurrent insider accumulation, occurs at a severe markdown from recent highs and against a backdrop of severe financial deterioration and losses.

CFO Newton buys 200.0K shares of LYEL at $0.56 in cluster buy; stock at $9.67, -83.9% from 52-week high

Newton Charles W., CFO of Lyell Immunopharma, purchased 200,000 shares at $0.56, establishing an initial position worth $111.6K. This transaction coincides with a cluster pattern: 2 other insiders also bought within the past 14 days. The broader context is material: LYEL has declined -83.9% from its 52-week high of $60.20 and faces fundamental headwinds, including quarterly revenue of $34.0K, a net loss of $-44.6M in the most recent period, and annual revenue contraction of -53.1%. The stock is down -20.8% over the past 30 days and -18.7% over 90 days. Concurrent buying by multiple insiders during steep price declines and deteriorating financials warrants examination of whether this reflects informed conviction about company trajectory or liquidity/hedging motives unrelated to valuation.